Tacrolimus dye drop treatment for the management of early post‑operative intraocular inflammation after therapeutic keratoplasty for severe infectious keratitis

Zang,Yunxiao; Li,Shang; Ruan,Fang; Liu,Zhaochuan; Jie,Ying

doi:10.3892/etm.2020.9057

Tacrolimus dye drop treatment for the management of early post‑operative intraocular inflammation after therapeutic keratoplasty for severe infectious keratitis

Authors:
- Yunxiao Zang
- Shang Li
- Fang Ruan
- Zhaochuan Liu
- Ying Jie
View Affiliations

Affiliations: Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Institute of Ophthalmology, Capital Medical University, Beijing 100730, P.R. China, Department of Ophthalmology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China
Published online on: July 28, 2020 https://doi.org/10.3892/etm.2020.9057
Pages: 3260-3268
Copyright: © Zang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study investigated the anti-inflammatory effect of 0.1% tacrolimus eye drops for the treatment of therapeutic penetrating keratoplasty (TPK) for severe infectious keratitis during early disease stages and reported the long‑term clinical outcomes. The present retrospective study included 20 eyes from patients diagnosed with severe keratitis who underwent TPK surgery. Patients were followed‑up for up to 12‑18 months. Tacrolimus eye drops were administered 4 times/day starting on the first day post‑surgery. Glucocorticoid eye drops were subsequently added to treatment plans one‑month post‑surgery. All patients were followed‑up for the first 3 post‑operative days, then examined once a week thereafter for the first month. In early post‑operative stages, the states of the grafts (ΔS) and the absorption of intraocular inflammation (S) were observed. ΔS was defined as the difference between the states of the grafts on the first post‑operative day (SS1d) and those at one month post‑surgery (SS1m). S was calculated as the difference between the inflammation score mean one day post‑surgery (T1d) and the mean one‑month post‑surgery (T1m). For long term clinical outcomes, graft failure rates and complications were recorded. Among the 20 eyes analyzed, the mean T1d, T1m and S were 7.4±2.06, 2.0±2.47 and 5.4±2.13 (P<0.01), respectively. The mean SS1d, SS1m and ΔS were 5.3±1.56, 3.8±1.24 and 1.5±1.5 (P<0.01), respectively. During follow‑up, there were 6 cases of corneal graft failure, 4 of which were due to immune rejection and 2 of which were due to complications. The current study concluded that tacrolimus eye drops facilitated the absorption of intraocular inflammation in the early post‑operative period of TPK and may extend long term survival of grafts in cases of severe infectious keratitis.

View Figures

View References

1	Jones DB: Decision-making in the management of microbial keratitis. Ophthalmology. 88:814–820. 1981.PubMed/NCBI View Article : Google Scholar
2	Yang JW, Lin HC, Hsiao CH and Chen PY: Therapeutic penetrating keratoplasty in severe infective keratitis using glycerol-preserved donor corneas. Cornea. 31:1103–1106. 2012.PubMed/NCBI View Article : Google Scholar
3	Ti SE, Scott JA, Janardhanan P and Tan DT: Therapeutic keratoplasty for advanced suppurative keratitis. Am J Ophthalmol. 143:755–762. 2007.PubMed/NCBI View Article : Google Scholar
4	Sharma N, Sachdev R, Jhanji V, Titiyal JS and Vajpayee RB: Therapeutic keratoplasty for microbial keratitis. Curr Opin Ophthalmol. 21:293–300. 2010.PubMed/NCBI View Article : Google Scholar
5	Cohen RA, Gebhardt BM and Bazan NG: A platelet-activating factor antagonist reduces corneal allograft inflammation and neovascularization. Curr Eye Res. 13:139–144. 1994.PubMed/NCBI View Article : Google Scholar
6	Rahman I, Carley F, Hillarby C, Brahma A and Tullo AB: Penetrating keratoplasty: Indications, outcomes, and complications. Eye (Lond). 23:1288–1294. 2009.PubMed/NCBI View Article : Google Scholar
7	Shi W, Wang T, Xie L, Li S, Gao H, Liu J and Li H: Risk factors, clinical features, and outcomes of recurrent fungal keratitis after corneal transplantation. Ophthalmology. 117:890–896. 2010.PubMed/NCBI View Article : Google Scholar
8	MacMillan D: FK506 binding proteins: Cellular regulators of intracellular Ca2+ signalling. Eur J Pharmacol. 700:181–193. 2013.PubMed/NCBI View Article : Google Scholar
9	Magalhaes OA, Marinho DR and Kwitko S: Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: A cohort study. Br J Ophthalmol. 97:1395–1398. 2013.PubMed/NCBI View Article : Google Scholar
10	Wan Q, Tang J, Han Y, Wang D and Ye H: Therapeutic effect of 0.1% tacrolimus eye drops in the tarsal form of vernal keratoconjunctivitis. Ophthalmic Res. 59:126–134. 2018.PubMed/NCBI View Article : Google Scholar
11	Lee YJ, Kim SW and Seo KY: Application for tacrolimus ointment in treating refractory inflammatory ocular surface diseases. Am J Ophthalmol. 155:804–813. 2013.PubMed/NCBI View Article : Google Scholar
12	Tam PM, Young AL, Cheng LL and Lam PT: Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD. Bone Marrow Transplant. 45:957–958. 2010.PubMed/NCBI View Article : Google Scholar
13	Abudou M, Wu T, Evans JR and Chen X: Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty. Cochrane Database Syst Rev. (CD007603)2015.PubMed/NCBI View Article : Google Scholar
14	Yamazoe K, Yamazoe K, Yamaguchi T, Omoto M and Shimazaki J: Efficacy and safety of systemic tacrolimus in high-risk penetrating keratoplasty after graft failure with systemic cyclosporine. Cornea. 33:1157–1163. 2014.PubMed/NCBI View Article : Google Scholar
15	Miedziak AI, Miller MR, Rapuano CJ, Laibson PR and Cohen EJ: Risk factors in microbial keratitis leading to penetrating keratoplasty. Ophthalmology. 106:1166–1171. 1999.PubMed/NCBI View Article : Google Scholar
16	Skeens HM and Holland EJ: Large-diameter penetrating keratoplasty: Indications and outcomes. Cornea. 29:296–301. 2010.PubMed/NCBI View Article : Google Scholar
17	Jia Y, Gao H, Li S and Shi W: Combined anterior chamber washout, amniotic membrane transplantation, and topical use of corticosteroids for severe peripheral ulcerative keratitis. Cornea. 33:559–564. 2014.PubMed/NCBI View Article : Google Scholar
18	Cohen EJ, Kenyon KR and Dohlman CH: Iridoplasty for prevention of post-keratoplasty angle closure and glaucoma. Ophthalmic Surg. 13:994–996. 1982.PubMed/NCBI
19	Mannis MJ and Holland EJ: Cornea-surgery of the cornea and conjunctiva. Fourth edition. Elsevier. 1,2(pp1952)2016.
20	Kharod-Dholakia B, Randleman JB, Bromley JG and Stulting RD: Prevention and treatment of corneal graft rejection: Current practice patterns of the Cornea Society (2011). Cornea. 34:609–614. 2015.PubMed/NCBI View Article : Google Scholar
21	Jabs DA, Nussenblatt RB and Rosenbaum JT: Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 140:509–516. 2005.PubMed/NCBI View Article : Google Scholar
22	Sloper CM, Powell RJ and Dua HS: Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology. 108:1838–1844. 2001.PubMed/NCBI View Article : Google Scholar
23	Rinne JR and Stulting RD: Current practices in the prevention and treatment of corneal graft rejection. Cornea. 11:326–328. 1992.PubMed/NCBI View Article : Google Scholar
24	Williams KA, Roder D, Esterman A, Muehlberg SM and Coster DJ: Factors predictive of corneal graft survival. Report from the Australian corneal graft registry. Ophthalmology. 99:403–414. 1992.PubMed/NCBI View Article : Google Scholar
25	Panda A, Vanathi M, Kumar A, Dash Y and Priya S: Corneal graft rejection. Surv Ophthalmol. 52:375–396. 2007.PubMed/NCBI View Article : Google Scholar
26	Snyder RW, Sherman MD and Allinson RW: Intracameral tissue plasminogen activator for treatment of excessive fibrin response after penetrating keratoplasty. Am J Ophthalmol. 109:483–484. 1990.PubMed/NCBI View Article : Google Scholar
27	Yu Y, Zhong J, Peng L, Wang B, Li S, Huang H, Deng Y, Zhang H, Yang R, Wang C and Yuan J: Tacrolimus downregulates inflammation by regulating pro-/anti-inflammatory responses in LPS-induced keratitis. Mol Med Rep. 16:5855–5862. 2017.PubMed/NCBI View Article : Google Scholar
28	Sakuma S, Higashi Y, Sato N, Sasakawa T, Sengoku T, Ohkubo Y, Amaya T and Goto T: Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). Int Immunopharmacol. 1:1219–1226. 2001.PubMed/NCBI View Article : Google Scholar
29	Flower RJ: Eleventh Gaddum memorial lecture. Lipocortin and the mechanism of action of the glucocorticoids. Br J Pharmacol. 94:987–1015. 1988.PubMed/NCBI View Article : Google Scholar
30	Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, Nourse J and Crabtree GR: The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 80:S40–S45. 1996.PubMed/NCBI View Article : Google Scholar
31	Küchle M, Nguyen NX and Naumann GO: Aqueous flare following penetrating keratoplasty and in corneal graft rejection. Arch Ophthalmol. 112:354–358. 1994.PubMed/NCBI View Article : Google Scholar
32	Xie L and Shi W: Comparison of immunological response after penetrating keratoplasty for three kinds of infectious corneal ulcers. Chin J Ophthalmol. 18:249–251. 2000.(In Chinese).
33	Dandona L, Naduvilath TJ, Janarthanan M, Ragu K and Rao GN: Survival analysis and visual outcome in a large series of corneal transplants in India. Br J Ophthalmol. 81:726–731. 1997.PubMed/NCBI View Article : Google Scholar
34	Weisbrod DJ, Sit M, Naor J and Slomovic AR: Outcome of repeat penetrating keratoplasty and risk factors for graft failure. Cornea. 22:429–434. 2003.PubMed/NCBI View Article : Google Scholar
35	Li C, Zhao GQ, Che CY, Lin J, Li N, Jia WY, Zhang QQ, Jiang N and Hu LT: Effect of corneal graft diameter on therapeutic penetrating keratoplasty for fungal keratitis. Int J Ophthalmol. 5:698–703. 2012.PubMed/NCBI View Article : Google Scholar
36	Price MO, Thompson RW Jr and Price FW Jr: Risk factors for various causes of failure in initial corneal grafts. Arch Ophthalmol. 121:1087–1092. 2003.PubMed/NCBI View Article : Google Scholar
37	Sukhija J and Jain AK: Outcome of therapeutic penetrating keratoplasty in infectious keratitis. Ophthalmic Surg Lasers Imaging. 36:303–309. 2005.PubMed/NCBI